Keybank National Association OH raised its stake in Grifols, S.A. (NASDAQ:GRFS) by 2.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,110 shares of the biotechnology company’s stock after acquiring an additional 1,124 shares during the quarter. Keybank National Association OH’s holdings in Grifols, were worth $911,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of GRFS. Vaughan Nelson Investment Management L.P. bought a new position in Grifols, during the 2nd quarter worth approximately $57,845,000. FMR LLC raised its holdings in Grifols, by 52.6% during the 1st quarter. FMR LLC now owns 6,352,581 shares of the biotechnology company’s stock worth $119,905,000 after purchasing an additional 2,189,431 shares during the last quarter. AKO Capital LLP raised its holdings in Grifols, by 5.7% during the 2nd quarter. AKO Capital LLP now owns 12,341,363 shares of the biotechnology company’s stock worth $9,335,000 after purchasing an additional 667,174 shares during the last quarter. NGAM Advisors L.P. raised its holdings in Grifols, by 661.8% during the 2nd quarter. NGAM Advisors L.P. now owns 632,072 shares of the biotechnology company’s stock worth $13,356,000 after purchasing an additional 549,097 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its holdings in Grifols, by 7.8% during the 2nd quarter. Pictet Asset Management Ltd. now owns 5,409,186 shares of the biotechnology company’s stock worth $116,081,000 after purchasing an additional 390,486 shares during the last quarter. Institutional investors and hedge funds own 21.93% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Grifols, S.A. (GRFS) Shares Bought by Keybank National Association OH” was first reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/keybank-national-association-oh-has-911000-holdings-in-grifols-s-a-grfs/1600140.html.
GRFS has been the subject of several recent analyst reports. BidaskClub raised shares of Grifols, from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research raised shares of Grifols, from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, July 4th. Bank of America Corporation reissued a “buy” rating on shares of Grifols, in a research report on Tuesday, July 4th. Finally, Goldman Sachs Group, Inc. (The) downgraded shares of Grifols, from a “buy” rating to a “neutral” rating in a research report on Friday, June 30th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $24.00.
Shares of Grifols, S.A. (NASDAQ:GRFS) opened at 21.41 on Friday. The company has a market capitalization of $29.25 billion, a PE ratio of 43.73 and a beta of 1.00. The stock’s 50 day moving average price is $20.66 and its 200-day moving average price is $20.28. Grifols, S.A. has a 1-year low of $14.27 and a 1-year high of $22.83.
Grifols, Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with our FREE daily email newsletter.